Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-2 adjuvant camizestrant versus standard endocrine therapy in early ER-positive/HER2-negative breast cancer
MOH_2023-08-17_012888Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-08-17_012888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-17_012888.